Corbus Pharma Reports Director/Officer Changes & Compensation
Ticker: CRBP · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1595097
Sentiment: neutral
Topics: management-change, officer-appointment, director-election, compensation
Related Tickers: CRBP
TL;DR
Corbus Pharma's 8-K details leadership changes and executive pay adjustments.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on December 18, 2025, reporting on events as of December 12, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. The company is incorporated in Delaware and its principal executive offices are located in Norwood, Massachusetts.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensation adjustments, can signal internal shifts that may carry associated risks.
Key Numbers
- 20251212 — Date of Earliest Event Reported (Indicates the effective date for the reported events.)
- 20251218 — Filing Date (The date the 8-K was officially submitted to the SEC.)
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Norwood, Massachusetts (location) — Principal Executive Offices
- SAV Acquisition Corp (company) — Former Company Name
FAQ
Who specifically departed from Corbus Pharmaceuticals Holdings, Inc. as a director or officer?
The filing does not specify the names of the directors or officers who departed.
Who were elected as new directors for Corbus Pharmaceuticals Holdings, Inc.?
The filing does not name the individuals elected as new directors.
Were any new officers appointed to Corbus Pharmaceuticals Holdings, Inc.?
The filing indicates the appointment of certain officers but does not name them.
What specific compensatory arrangements were made for certain officers?
The filing mentions compensatory arrangements but does not detail the specifics of these arrangements.
What was the previous name of Corbus Pharmaceuticals Holdings, Inc.?
The previous name of the company was SAV Acquisition Corp.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 12.8 · Accepted 2025-12-18 16:05:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20251212.htm (8-K) — 42KB
- 0001193125-25-324796.txt ( ) — 152KB
- crbp-20251212.xsd (EX-101.SCH) — 31KB
- crbp-20251212_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: December 18, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer